Shao Weifang, Xu Yanhua, Lin Suzhen, Gao Junli, Gao Junshun, Wang Hong
Medical Laboratory Department, ChangXing People Hospital, Hangzhou City, China.
Hangzhou Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School, Hangzhou City, China.
Front Oncol. 2022 Aug 16;12:988567. doi: 10.3389/fonc.2022.988567. eCollection 2022.
Colorectal cancer (CRC) is one of the most significant neoplasms with high morbidity and mortality. Activation of the programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) signaling pathway results in tumor immune evasion by suppressing the activity of T cells. The correlation of soluble PD-L1 (sPD-L1) in serum/plasma with clinicopathological features, lymph node metastasis, diagnosis and prognosis is less clear. The aim of this study was to investigate the relationship between sPD-L1 and clinicopathological features, and diagnosis potentialof CRC. Three hundred patients with CRC were included in this study. sPD-L1 was measured by ELISA. Pretreatment levels of sPD-L1 were significantly elevated in CRC patient sera compared to healthy control (HC) (<0.001). The median value of sPD-L1 in HC, CRC with non-lymph node metastasis, and CRC with lymph node metastasis were 246.78±50.2pg/mL, 284.12±52.7pg/mL, and 321.31±55.3pg/mL, respectively. ROC analysis of sPD-L1 allowed significant differentiation between HC group and CRC group (lymph node metastasis and non lymph node metastasis (AUC=0.861, 95% CI 0.830-0.887, p<0.001). sPD-L1 is a potential biomarker for the diagnosis of CRC. Multivariate analysis showed that lymph node metastasis and tumor differentiation were independent prognostic factors (all < 0.01), and sPD-L1 was not correlated with the CRC prognosis (>0.05).
结直肠癌（CRC）是发病率和死亡率都很高的最重要的肿瘤之一。程序性死亡蛋白1/程序性死亡配体1（PD-1/PD-L1）信号通路的激活通过抑制T细胞活性导致肿瘤免疫逃逸。血清/血浆中可溶性PD-L1（sPD-L1）与临床病理特征、淋巴结转移、诊断及预后的相关性尚不清楚。本研究旨在探讨sPD-L1与CRC临床病理特征之间的关系以及CRC的诊断潜力。本研究纳入了300例CRC患者。采用酶联免疫吸附测定法（ELISA）检测sPD-L1。与健康对照（HC）相比，CRC患者血清中sPD-L1的预处理水平显著升高（<0.001）。HC组、无淋巴结转移的CRC组和有淋巴结转移的CRC组中sPD-L1的中位数分别为246.78±50.2pg/mL、284.12±52.7pg/mL和321.31±55.3pg/mL。对sPD-L1进行的ROC分析能够显著区分HC组和CRC组（淋巴结转移和无淋巴结转移，AUC=0.861，95%CI 0.830-0.887，p<0.001）。sPD-L1是CRC诊断的潜在生物标志物。多因素分析显示，淋巴结转移和肿瘤分化是独立的预后因素（均<0.01），且sPD-L1与CRC预后无关（>0.05）。
